These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30227045)

  • 1. Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials.
    Shapley S; O'Shaughnessy J; Woodcock J
    Ther Innov Regul Sci; 2017 Jul; 51(4):416-418. PubMed ID: 30227045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An FDA Analysis of Formal Dispute Resolution in the Center for Drug Evaluation and Research: 2003 Through 2014.
    Sharma K; Harrington A; Worrell S; Bertha A
    Ther Innov Regul Sci; 2016 Nov; 50(6):697-704. PubMed ID: 30231744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development.
    Bhagat R; Bojarski L; Chevalier S; Görtz DR; Le Meignen S; Makowski M; Nadolny P; Pillwein M; Suprin M; Turri S
    Ther Innov Regul Sci; 2021 Mar; 55(2):251-261. PubMed ID: 32885397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples.
    Geanacopoulos M; Barratt R
    Ther Innov Regul Sci; 2015 Jul; 49(4):466-472. PubMed ID: 30222436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective.
    Johnson FR; Zhou M
    Value Health; 2016; 19(6):741-745. PubMed ID: 27712700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stakeholders' recommendations for revising Good Clinical Practice.
    Corneli A; Forrest A; Swezey T; Lin L; Tenaerts P
    Contemp Clin Trials Commun; 2021 Jun; 22():100776. PubMed ID: 33997463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paving the critical path of drug development: the CDER perspective.
    Woodcock J
    Nat Rev Drug Discov; 2014 Nov; 13(11):783-4. PubMed ID: 25359359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science.
    Rouse R; Kruhlak N; Weaver J; Burkhart K; Patel V; Strauss DG
    Ther Innov Regul Sci; 2018 Mar; 52(2):244-255. PubMed ID: 29568713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Council for Harmonisation E6(R2) addendum: Challenges of implementation.
    Bhatt A
    Perspect Clin Res; 2017; 8(4):162-166. PubMed ID: 29109932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview.
    Woodcock J; Buckman S; Goodsaid F; Walton MK; Zineh I
    Expert Opin Med Diagn; 2011 Sep; 5(5):369-74. PubMed ID: 23484625
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.